[1]吴 戈,蔡 瑜△,贾媛媛,等.塞来昔布联合化疗治疗晚期胃癌疗效与安全性Meta分析*[J].陕西医学杂志,2020,49(3):364-369.
　WU Ge,CAI Yu,JIA Yuanyuan,et al.Efficacy and safety of celecoxib combined with chemotherapy versus chemortherapy alone in the treatment of advanced gastric cancer:a meta-analysis[J].,2020,49(3):364-369.
点击复制

塞来昔布联合化疗治疗晚期胃癌疗效与安全性Meta分析*
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
49
期数:
2020年3期
页码:
364-369
栏目:
Meta分析
出版日期:
2020-03-05

文章信息/Info

Title:
Efficacy and safety of celecoxib combined with chemotherapy versus chemortherapy alone in the treatment of advanced gastric cancer:a meta-analysis
文章编号:
DOI:〖HT5K〗10.3969/j.issn.10007377.2020.03.026
作者:
吴 戈1; 蔡 瑜1△; 贾媛媛1; 李武军1; 2; 于照祥1; 张青青1
1.西安医学院第一附属医院(西安 710077); 2.西藏自治区阿里地区人民医院(阿里 859000)
Author(s):
WU Ge; CAI Yu; JIA Yuanyuan; et al.
First Affiliated Hospital Of Xi'an Medical University( Xi'an 710077)
关键词:
塞来昔布;  环氧化酶2抑制剂;  胃癌;  系统评价;  Meta分析;  安全性
Keywords:
Celecoxib;  Cyclooxygenase-2 inhibitor;  Gastric cancer;  Systematic evaluation;  Meta analysis;  Safety
分类号:
R735.2
文献标志码:
A
摘要:
目的:系统性评价塞来昔布联合化疗治疗晚期胃癌的有效性、安全性。方法:检索CNKI知网、万方、维普和Pub Med数据库,搜集塞来昔布联合化疗治疗晚期胃癌的随机对照试验(RCT),检索时限为建库至2018年12月10日。在评价纳入研究的偏倚风险后,采用Stata14.0软件进行Meta分析。结果:共纳入8个RCT,结果显示塞来昔布联合化疗组治疗有效率[RR=1.42,95%CI(1.21～1.68),P<0.001]、疾病控制率[RR=1.15,95%CI(1.04～1.27),P<0.001]、生活质量改善状况[RR=1.61,95%CI(1.32～1.95),P<0.001]均优于常规化疗组,并且可降低恶心呕吐[RR=0.81,95%CI(0.69～0.96),P=0.014]、血小板减少[RR=0.78,95%CI(0.64～0.96),P=0.017]事件的发生率,但两组在贫血、白细胞减少、腹泻、手足综合征、外周神经炎等事件发生率方面比较差异无统计学意义。结论:塞来昔布联合化疗较单纯化疗在晚期胃癌治疗方面的疗效更好,且安全性较好。
Abstract:
Objectives:To systematically review the efficacy and safety of celecoxib combined with chemotherapy for advanced gastric cancer.Methods:Databases including VIP,CNKI,WanFang Data and PubMed were electronically searched from inception to December 2018 to collect randomized controlled trials(RCT)on celecoxib combined with chemotherapy versus chemotherapy alone for advanced gastric cancer.After evaluating the risk of bias in the included studies,Stata 14.0 software was used for meta-analysis.Results:A total of 8 RCTs were included.The results of meta-analysis showed that the therapeutic efficacy(RR=1.42,95%CI 1.21 to 1.68,P<0.001),disease control rate(RR=1.15,95%CI 1.04 to 1.27,P<0.001),and quality of life improvement(RR=1.61; 95%CI,1.32 to 1.95; P<0.001)of celecoxib combined with chemotherapy group were superior to those of conventional chemotherapy group.Moreover,the incidence of nausea and vomiting(RR=0.81,95%CI 0.69 to 0.96,P=0.014),and thrombocytopenia(RR=0.78,95%CI 0.64 to 0.96,P=0.017)was reduced,but there was no statistical difference in the incidence of events such as anemia,leukopenia,diarrhea,hand-foot syndrome,and peripheral neuritis.Conclusion:Celecoxib combined with chemotherapy is more effective and safer than chemotherapy alone in the treatment of advanced gastric cancer.

参考文献/References:

[1] Gastric Cancer Treatment(PDQR):Health Professional Version.PDQAdultTreatment Editorial Board.PDQ Cancer Information Summaries [Internet].Bethesda(MD):National Cancer Institute(US); 2002-2018,17.
[2] Chen W,Zheng R,Baade PD,et al.Cancer statistics in China,2015[J].Ca Cancer J Clin,2016,66(2):115-132.
[3] Liao X,Chaudhary P,Qiu G,et al.The role of propranolol as a radiosensitizer in gastric cancer treatment[J].Drug Des Devel Ther,2018,28,(12):639-645.
[4] Ren J,Liu J,Sui X.Correlation of COX-2 and MMP-13 expressions with gastric cancer and their effects on prognosis[J].J BUON,2018,23(3):665-671.
[5] Vallecillo-Hernández J,Barrachina MD,Ortiz-Masiá D,et al.Indomethacin disrupts autophagic flux by inducing lysosomal dysfunction in gastric cancer cells and increases their sensitivity to cytotoxic drugs[J].Sci Rep,2018,8(1):3593.
[6] Tolloczko-Iwaniuk N,Dziemianczyk-Pakiela D,Nowaszewska BK,et al.Celecoxib in cancer therapy and prevention-review[J].Curr Drug Targets,2018,PMID:30073924[Epub ahead of print].
[7] 杨海劲,田 丹,吴 剑.塞来昔布联合CapeOX方案治疗晚期胃癌的近期效果[J].中国当代医药,2018,25(2 0):57-59.
[8] 任晓晓,张小茜,张红梅,等.塞来昔布联合FOLFOX4方案治疗晚期胃癌的疗效及机制研究[J].中国现代医学杂志,2018,28(15):27-31.
[9] 郜娜娜,马 馨,贺新爱.塞来昔布联合化疗治疗晚期胃癌的疗效分析[J].中国癌症防治杂志,2017,(6):478-481.
[10] 田 丹,汪森明,李华珍.塞来昔布联合XELOX方案治疗晚期胃癌的临床研究[J].广州医科大学学报,2017,45(1):63-65.
[11] 杨海劲.XELOX-C方案与XELOX方案对胃癌患者的疗效及安全性分析[J].首都食品与医药,2016,23(14):34-36.
[12] 寇卫政,杨留中,褚秀峰,等.替吉奥联合塞来昔布治疗晚期胃癌疗效观察[J].新乡医学院学报,2015,32(4):336-339.
[13] 潘战和,苏 安,王 馨,等.环氧合酶-2抑制剂联合XELOX方案一线治疗晚期胃癌24例[J].世界华人消化杂志,2013,21(3):261-265.
[14] 付 曦,李光明,任大成,等.塞来昔布/希罗达节拍化疗治疗老年晚期胃癌的临床研究[J].华西医学,2009,(8):2027-2030.
[15] Xu HB,Shen FM,Lv QZ.Celecoxib enhanced the cytotoxic effect of cisplatin in drug-resistant human gastric cancer cells by inhibition of cyclooxygenase-2[J].Eur J Pharmacol,2015,769(15):1-7.
[16] Kong P,Wu R,Liu X,et al.The effects of anti-inflammatory drug treatment in gastric cancer prevention:an Update of a Meta-analysis[J].J Cancer,2016,7(15):2247-2257.
[17] YeY,Liu M,Yuan H,et al.COX-2 regulates snail expression in gastric cancer via the notch1 signaling pathway[J].Int J Mol Med,2017,40(2):512-522.
[18] Li Q,Peng J,Liu T,et al.Effects of celecoxib on cell apoptosis and Fas,FasL and Bcl-2 expression in a BGC-823 human gastric cancer cell line[J].Exp Ther Med,2017,14(3):1935-1940.
[19] Jin GH,Xu W,Shi Y,et al.Celecoxib exhibits an anti-gastric cancer effect by targeting focal adhesion and leukocyte transendothelial migration-associated genes[J].Oncol Lett,2016,12(4):2345-2350.
[20] Aziz F,Yang X,Wang X,et al.Anti-LeY antibody enhances therapeutic efficacy of celecoxib against gastric cancer by downregulation of MAPKs/COX-2 signaling pathway:correlation with clinical study[J].J Cancer Res Clin Oncol,2015,141(7):1221-1235

备注/Memo

备注/Memo:
*西藏自治区阿里地区科技创新支撑类自然科学基金资助项目(AKKCZRJJ20180207)
更新日期/Last Update: 2020-03-25